Who are MPL-001 (CBD: THC 25:1)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MediCabilis CBD Oil, Cannabidiol (CBD) Oil Capsules, Cannabidiol (CBD) Extract, Placebo Matched to Low-Dose Cannabidiol, Moderate-Dose Cannabidiol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mpl-001-cbd-thc-25-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MPL-001 (CBD: THC 25:1) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MPL-001 (CBD: THC 25:1) (MPL-001 (CBD: THC 25:1)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid combination.

phase 3 Cannabinoid combination CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor Small molecule Live · refreshed every 30 min

Target snapshot

MPL-001 (CBD: THC 25:1) (MPL-001 (CBD: THC 25:1)) — McMaster University. MPL-001 is a cannabinoid combination product that modulates endocannabinoid signaling through CBD and THC at a 25:1 ratio to produce therapeutic effects.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MPL-001 (CBD: THC 25:1) TARGET	MPL-001 (CBD: THC 25:1)	McMaster University	phase 3	Cannabinoid combination	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Cannabidiol (CBD) Oil Capsules	Cannabidiol (CBD) Oil Capsules	McMaster University	phase 3	Phytocannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multi-target)
Cannabidiol (CBD) Extract	Cannabidiol (CBD) Extract	Milton S. Hershey Medical Center	phase 3	Cannabinoid receptor modulator	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
Placebo Matched to Low-Dose Cannabidiol	Placebo Matched to Low-Dose Cannabidiol	Wayne State University	phase 3	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
Moderate-Dose Cannabidiol	Moderate-Dose Cannabidiol	Wayne State University	phase 3	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid combination class)

McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MPL-001 (CBD: THC 25:1) — Competitive Intelligence Brief. https://druglandscape.com/ci/mpl-001-cbd-thc-25-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab